Amicus Therapeutics (NASDAQ:FOLD) is a biotechnology firm focused on discovering, developing, and delivering novel treatments for people living with rare metabolic diseases. With a strong commitment to innovation, Amicus Therapeutics has built a diverse pipeline of therapies aimed at addressing unmet medical needs in conditions that are often overlooked by larger pharmaceutical companies. Among its key projects is the development of enzyme replacement therapies designed to treat genetic disorders at their source. The company's main objective is to provide transformative therapies that improve the quality of life for patients and their families. Through a combination of strategic collaborations and proprietary technologies, Amicus Therapeutics strives to push the boundaries of science and medicine to bring forward potentially life-changing medicines.